Submitted Successfully!
Thank you for your contribution! You can also upload a video entry related to this topic through the link below:
Check Note
Ver. Summary Created by Modification Content Size Created at Operation
1 + 1814 word(s) 1814 2021-11-19 04:29:47 |
2 The format is correct. + 2 word(s) 1816 2021-12-07 03:05:00 |
Catatonia: Diagnosis, Treatment and Clinical Challenges
Upload a video

Catatonia is a syndrome that has been associated with several mental illness disorders but that has also presented as a result of other medical conditions. It is defined as a group of symptoms that involve a lack of movement as well as a lack of communication. It can be accompanied by agitation, confusion, and restlessness. Schizophrenia and other psychiatric disorders such as mania and depression are known to be associated with catatonia. The treatment of catatonia often involves the use of benzodiazepines, such as lorazepam, that can be used in combination therapy with antipsychotics. Definitive treatment may be found with electroconvulsive therapy (ECT).

  • schizophrenia
  • catatonia
  • benzodiazepines
  • ECT
Subjects: Neurosciences
Contributors : , , ,
View Times: 73
Revisions: 2 times (View History)
Update Time: 07 Dec 2021

1. Catatonia Causes, Presentation, and Pathophysiology

1.1. Types of Catatonia

There are three types of catatonia that clinicians need to be aware of. The first, and most common, is akinetic catatonia. A patient with this type of catatonia will stare and appears to be non-responsive [1]. Response to vocal and noxious stimuli is decreased [2]. These patients are alert and aware of their surroundings. The second type of catatonia is excited catatonia. A patient with this type may move, but their movements seem pointless and impulsive. They can appear agitated, combative, or even delirious [1]. The excess motor activity could cause either harm to the patient themself or harm to others [2]. The last type is malignant catatonia. This type of catatonia is dangerous and is associated with autonomic instability [1]. This can be seen in neuroleptic malignant syndrome and can signal a potential lethal underlying cause of the catatonia. Malignant catatonia can evolve rapidly, within a matter of days [3]. It is because of this rapid evolution that clinicians need to keep this in mind when seeing a person with suspected catatonia and act quickly to treat the underlying cause.
Although not an official subtype of catatonia, periodic catatonia can present as a diagnostic challenge for clinicians and should be discussed. Periodic catatonia is a rare form of catatonia where the symptoms present in phases and can disappear completely in between episodes [4]. The pathophysiology of periodic catatonia is unclear at this time, though it may be related to a dysfunctional GABA signal since acute cases respond well to benzodiazepines [5]. There have been cases reported where treatment with an atypical antipsychotic relieved symptoms [5].

1.2. Causes

It is important to note that catatonia is a constellation of symptoms that are a result of an underlying disorder. Catatonia itself is not a disorder but rather a syndrome. Psychiatric disorders are the first source that comes to mind when thinking about the underlaying causes of catatonia. Patients with bipolar disorder, autism, schizophrenia, major depressive disorder, or mixed psychiatric conditions all have a higher incidence of catatonia than the general population [6]. In fact, roughly 35% of individuals with schizophrenia will show symptoms of catatonia at some point [7]. It is because of this that it is important to keep catatonia in mind in patients with schizophrenia when abnormal movement and communication is present, as this could be a presentation of neuroleptic malignant syndrome, a life-threatening syndrome that can be caused by antipsychotic use. Roughly 20% of patients with catatonia have a medical cause rather than a psychiatric one [8]. Additionally, general medical conditions such as strokes, neoplasms, infections, autoimmune disorders, neurodegenerative diseases, metabolic derangements, and certain drugs have all been associated with catatonia [8]. Infectious and autoimmune etiologies account for roughly 29% of cases associated with general medical causes, and studies have shown that meningitis and encephalitis as well as systemic bacterial, viral, or fungal infections may result in catatonia [9]. Further, autoimmune processes, particularly N-methyl-D-aspartate receptor (NMDAR) encephalitis and systemic lupus erythematous (SLE) also have a strong association with catatonia [9]. In fact, NMDAR encephalitis is responsible for 72% of all autoimmune cases of catatonia. The percentages presented in this section are meant to highlight that catatonia should be on the clinician’s radar whenever the syndrome is even slightly suspected. The exact reason why some medical conditions lead to catatonia is not well understood; however, direct neurotoxic effects, the patient’s psychological reaction to the insult, or mediation by acute phase reactants have all been suggested as potential causes [9][10].

1.3. Pathophysiology

The pathophysiology of catatonia is not currently well understood. However, recent studies suggest that three motor pathways within the brain and brainstem are responsible [11][12][13]. The first pathway leads from the primary motor cortex (M1) to the putamen, the internal and external pallidum, the thalamus, and then back to M1. This pathway is responsible for the inhibition and excitation of movements [12][13]. Another circuit runs between the M1, thalamus, cerebellum, and pontine nuclei and is responsible for motor dynamics and timing [11][12][13]. Lastly, the third circuit is composed of the M1, supplementary motor area (SMA), posterior parietal cortex, and medial prefrontal cortex and controls motor organization and speed [11][12][13]. The dysfunction of any of these circuits could lead to catatonic symptoms. Blood flow to the M1 and SMA has been shown to be increased in patients with catatonia compared to those without catatonia, further suggesting the increased neural activity of these circuits, likely resulting in catatonic behavior [14][15][16][17].
Reduced GABA activity, specifically GABA-A receptor activity, in the right lateral orbitofrontal and right posterior parietal cortex is thought to be another driver of the dysfunction seen in catatonia syndrome [18]. This dysfunction could explain the motor and affective symptoms seen in catatonia. This would explain why patients with catatonia respond well to and why benzodiazepines remain the mainstay of treatment for catatonia. This class of drugs stimulates GABA-A binding and relieves the symptoms of catatonia, presumably by lowering the increased neural activity in the circuits described above. Dysfunctional connections between the orbitofrontal cortex and the medial prefrontal cortices can be partially reversed by the administration of benzodiazepines, and imaging shows reduced GABA-A receptor density in cortical areas such as the left sensorimotor cortex [19][20]. Therefore, dysfunctional GABA-A signaling also seems to contribute to catatonia.

2. Catatonia Current Treatment

The early initiation of treatment in patients presenting with catatonia can reduce the risk of complications. When patients develop catatonia, their risk of developing deep venous thrombosis and pulmonary embolism increases substantially and occurs frequently [21]. This is due to the patient’s immobility. Other complications include malnutrition, infection, and muscle contractures, as the patient’s mobility is decreased, and they may refuse oral intake [22][23][24]. Despite the development of possible complications, most patients experience a resolution of symptoms with proper management [25]
The first-line treatment for catatonia is generally benzodiazepines, unless malignant catatonia is present. Benzodiazepines work on the GABA-A receptors and help to relieve the GABA dysfunction seen in some patients presenting with catatonia syndrome. Various benzodiazepines have been studied, and while lorazepam is typically used, others can also be considered, especially when additional symptoms or disorders are present. Caution must be used in patients exhibiting delirium, as their presentation can worsen; such patients may require lower doses for treatment [26]. When catatonia is suspected, a lorazepam challenge can be performed. This is done by giving a dose of lorazepam, either through IM or IV, and watching for a response. A response indicates the need for high suspicion of catatonia. In the case of substance-induced catatonia, a combination of lorazepam and diazepam has been shown to be an effective treatment plan, with the resolution of symptoms occurring within a day [27].
Electroconvulsive therapy (ECT) has been used to treat various mental disorders for many years and is an established treatment modality that has been proven to be highly effective for several conditions. Treatment involves brief electrical brain stimulations under anesthesia. ECT is a first-line treatment in neuroleptic malignant syndrome, malignant catatonia, and delirious catatonia. ECT is thought to work by increasing cerebral blood flow to the orbitofrontal and parietal cortices, which increases GABA activity and GABA receptor expression [28]. It can also be a definitive treatment when treatment with benzodiazepines has failed. The response rate of catatonia symptoms when ECT is used is around 80–100% [29] It can take several ECT treatments to achieve the desired results [30]. It can take at least six sessions for symptom relief to be seen [28]. The number of total ECT sessions needed cannot be predicted. The termination of ECT can be considered when a full clinical response is achieved or when there is further clinical improvement after two consecutive sessions [29].
Predictors of a favorable response to ECT are noted to be young age, the presence of autonomic dysregulation at baseline, daily ECT during the first week of treatment, longer duration of motor and EEG seizure activity at the final ECT sessions, and less morbidity in the year after ECT [29]. Contraindications to ECT include myocardial infarction within 3 months, elevated intracranial pressure, pheochromocytoma, cerebral tumors, and cerebral aneurysms [31]. Associated side effects may include impaired new learning, anterograde and retrograde amnesia, and autobiographical memory; these side effects usually resolve within weeks to months, but it may take up to 6 months for cognitive function to return to baseline [32][33][34]. A previous history of cognitive impairment places patients at higher risk of developing side effects [32]. If patients experience recurrent episodes, ECT may be continued for maintenance treatment [35].

3. Clinical Challenges

While ECT has been proven to produce a positive response in patients with catatonia, there are challenging aspects aside from the possible side effects resulting from this treatment modality. One such difficulty is obtaining consent from the patient. Patients in a catatonic state may be unable to provide full consent or refuse such treatment. In the USA, the guardian in these cases may make medical decisions; however, ECT treatment is typically not included, and a petition must be obtained [36]. A catatonic patient’s autonomy sets ethical challenges, as they are unable to fully comprehend the details of ECT treatment [36][37]. This same challenge presents in adolescent patients; however, healthcare professionals must consider the risks versus the benefits [37]. ECT has been found to be safe and effective in the pediatric population and is available as a form of treatment for them.
Other challenging aspects of catatonia involve its various forms of presentation, one of them being periodic catatonia. Periodic catatonia is a subtype of catatonia in which patients regularly experience multiple episodes. Although rare, it is a difficult subtype to diagnose and treat, as it may disappear before it can be treated [4]. Tang et al. describe a case of a 73-year-old woman with episodes of appearing ill for 45 years, which was initially thought to be a non-specific psychosis. She was initially placed on antipsychotics but was noted to have a good response to benzodiazepines. It was later discovered that her symptoms and presentation were consistent with periodic catatonia, and she was treated with multiple sessions of ECT. Her catatonia remained in remission for one year [38]. In patients presenting with multiple episodes of psychosis with symptoms meeting the criteria for catatonia, periodic catatonia should be considered in the differential diagnosis. Treating patients with antipsychotics in such cases may exacerbate catatonia and may induce neuroleptic malignant syndrome or malignant catatonia [39][40]. When neuroleptic malignant syndrome or malignant catatonia occurs, benzodiazepines have been proven to be an effective form of treatment for both conditions [40].


  1. Bhati, M.T.; Datto, C.J.; O’Reardon, J.P. Clinical Manifestations, Diagnosis, and Empirical Treatments for Catatonia. Psychiatry Edgmont Townsh 2007, 4, 46–52.
  2. Fink, M.; Taylor, M.A. The Catatonia Syndrome: Forgotten but Not Gone. Arch. Gen. Psychiatry 2009, 66, 1173.
  3. Northoff, G.; Wenke, J.; Pflug, B. Increase of serum creatine phosphokinase in catatonia: An investigation in 32 acute catatonic patients. Psychol. Med. 1996, 26, 547–553.
  4. Ghaffarinejad, A.R.; Sadeghi, M.M.; Estilaee, F.; Zokaee, Z. Periodic catatonia. Challenging diagnosis for psychiatrists. Neurosci Riyadh Saudi Arab. 2012, 17, 156–158.
  5. Guzman, C.S.; Myung, V.H.M.; Wang, Y.P. Treatment of periodic catatonia with atypical antipsychotic, olanzapine. Psychiatry Clin. Neurosci. 2008, 62, 482.
  6. Solmi, M.; Pigato, G.G.; Roiter, B.; Guaglianone, A.; Martini, L.; Fornaro, M.; Monaco, F.; Carvalho, A.F.; Stubbs, B.; Veronese, N.; et al. Prevalence of Catatonia and Its Moderators in Clinical Samples: Results from a Meta-analysis and Meta-regression Analysis. Schizophr. Bull. 2018, 44, 1133–1150.
  7. Stompe, T.; Ortwein-Swoboda, G.; Ritter, K.; Schanda, H.; Friedmann, A. Are we witnessing the disappearance of catatonic schizophrenia? Compr. Psychiatry 2002, 43, 167–174.
  8. Oldham, M.A. The Probability That Catatonia in the Hospital has a Medical Cause and the Relative Proportions of Its Causes: A Systematic Review. Psychosomatics 2018, 59, 333–340.
  9. Rogers, J.; A Pollak, T.; Blackman, G.; David, A. Catatonia and the immune system: A review. Lancet Psychiatry 2019, 6, 620–630.
  10. Haouzir, S.; Lemoine, X.; Desbordes, M.; Follet, M.; Meunier, C.; Baarir, Z.; Allio, G.; Menard, J.-F.; Briant, L.; Jouen, F.; et al. The role of coagulation marker fibrin D-dimer in early diagnosis of catatonia. Psychiatry Res. 2009, 168, 78–85.
  11. Hirjak, D.; Thomann, P.A.; Kubera, K.M.; Wolf, N.D.; Sambataro, F.; Wolf, R.C. Motor dysfunction within the schizophrenia-spectrum: A dimensional step towards an underappreciated domain. Schizophr. Res. 2015, 169, 217–233.
  12. Walther, S.; Stegmayer, K.; Wilson, J.E.; Heckers, S. Structure and neural mechanisms of catatonia. Lancet Psychiatry 2019, 6, 610–619.
  13. A Mittal, V.; A Bernard, J.; Northoff, G. What Can Different Motor Circuits Tell Us About Psychosis? An RDoC Perspective. Schizophr. Bull. 2017, 43, 949–955.
  14. Foucher, J.R.; Zhang, Y.F.; Roser, M.; Lamy, J.; De Sousa, P.L.; Weibel, S.; Vidailhet, P.; Mainberger, O.; Berna, F. A double dissociation between two psychotic phenotypes: Periodic catatonia and cataphasia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2018, 86, 363–369.
  15. Walther, S.; Schäppi, L.; Federspiel, A.; Bohlhalter, S.; Wiest, R.; Strik, W.; Stegmayer, K. Resting-State Hyperperfusion of the Supplementary Motor Area in Catatonia. Schizophr. Bull. 2016, 43, 972–981.
  16. Iseki, K.; Ikeda, A.; Kihara, T.; Kawamoto, Y.; Mezaki, T.; Hanakawa, T.; Hashikawa, K.; Fukuyama, H.; Shibasaki, H. Impairment of the cortical GABAergic inhibitory system in catatonic stupor: A case report with neuroimaging. Epileptic Disord 2009, 11, 126–131.
  17. De Tiege, X. Regional cerebral glucose metabolism in akinetic catatonia and after remission. J. Neurol. Neurosurg. Psychiatry 2003, 74, 1003–1004.
  18. Northoff, G.; Steinke, R.; Czcervenka, C.; Krause, R.; Ulrich, S.; Danos, P.; Kropf, D.; Otto, H.; Bogerts, B. Decreased density of GABA-A receptors in the left sensorimotor cortex in akinetic catatonia: Investigation of in vivo benzodiazepine receptor binding. J. Neurol. Neurosurg. Psychiatry 1999, 67, 445–450.
  19. Richter, A.; Grimm, S.; Northoff, G. Lorazepam modulates orbitofrontal signal changes during emotional processing in catatonia. Hum. Psychopharmacol. Clin. Exp. 2010, 25, 55–62.
  20. Northoff, G.; Kötter, R.; Baumgart, F.; Danos, P.; Boeker, H.; Kaulisch, T.; Schlagenhauf, F.; Walter, H.; Heinzel, A.; Witzel, T.; et al. Orbitofrontal Cortical Dysfunction in Akinetic Catatonia: A Functional Magnetic Resonance Imaging Study During Negative Emotional Stimulation. Schizophr. Bull. 2004, 30, 405–427.
  21. Worku, B.; Fekadu, A. Symptom profile and short term outcome of catatonia: An exploratory clinical study. BMC Psychiatry 2015, 15, 164.
  22. Francis, A. Catatonia: Diagnosis, Classification, and Treatment. Curr. Psychiatry Rep. 2010, 12, 180–185.
  23. Mader, J.E.C.; Rathore, S.H.; England, J.D.; Branch, L.A.; Copeland, B.J. Benzodiazepine Withdrawal Catatonia, Delirium, and Seizures in a Patient With Schizoaffective Disorder. J. Investig. Med. High Impact Case Rep. 2020, 8.
  24. Lin, C.-C.; Hung, Y.-Y.; Tsai, M.-C.; Huang, T.-L. The Lorazepam and Diazepam Protocol for Catatonia Due to General Medical Condition and Substance in Liaison Psychiatry. PLoS ONE 2017, 12, e0170452.
  25. Esienaert, P.; Dhossche, D.M.; Evancampfort, D.; Hert, M.E.; Gazdag, G. A Clinical Review of the Treatment of Catatonia. Front. Psychiatry 2014, 5, 181.
  26. Unal, A.; Altindag, A.; Demir, B.; Aksoy, I. The Use of Lorazepam and Electroconvulsive Therapy in the Treatment of Catatonia: Treatment Characteristics and Outcomes in 60 Patients. J. ECT 2017, 33, 290–293.
  27. Salik, I.; Marwaha, R. Electroconvulsive Therapy. In StatPearls; StatPearls Publishing: Treasure Island, FL, USA, 2020. Available online: (accessed on 12 June 2021).
  28. Selch, S.; Strobel, A.; Haderlein, J.; Meyer, J.; Jacob, C.P.; Schmitt, A.; Lesch, K.-P.; Reif, A. MLC1 Polymorphisms Are Specifically Associated with Periodic Catatonia, a Subgroup of Chronic Schizophrenia. Biol. Psychiatry 2007, 61, 1211–1214.
  29. Stöber, G.; Saar, K.; Rüschendorf, F.; Meyer, J.; Nürnberg, G.; Jatzke, S.; Franzek, E.; Reis, A.; Lesch, K.-P.; Wienke, T.F.; et al. Splitting Schizophrenia: Periodic Catatonia–Susceptibility Locus on Chromosome 15q15. Am. J. Hum. Genet. 2000, 67, 1201–1207.
  30. Petersen, J.Z.; Miskowiak, K.W. Cognitive side effects of electroconvulsive therapy. Ugeskr. laeger 2018, 180.
  31. Margittai, Z.; Yardimci, T.; Marin, D.; Kamp, D.; Cordes, J.; Kujovic, M. Cognitive deficits associated with electroconvulsive therapy for depression: Moderating factors and neuropsychological tests. Fortschr. Neurol. Psychiatr. 2018, 86, 690–698.
  32. Kellner, C.H.; Obbels, J.; Sienaert, P. When to consider electroconvulsive therapy (ECT). Acta Psychiatr. Scand. 2020, 141, 304–315.
  33. Stip, E.; Blain-Juste, M.-E.; Farmer, O.; Fournier-Gosselin, M.-P.; Lespérance, P. Catatonia with schizophrenia: From ECT to rTMS. L’Encéphale 2018, 44, 183–187.
  34. Plevin, D.; Mohan, T.; Bastiampillai, T. The role of the GABAergic system in catatonia—Insights from clozapine and benzodiazepines. Asian J. Psychiatry 2018, 32, 145–146.
  35. Zisselman, M.H.; Jaffe, R.L. ECT in the Treatment of a Patient With Catatonia: Consent and Complications. Am. J. Psychiatry 2010, 167, 127–132.
  36. Fink, M.; Taylor, M.A. The many varieties of catatonia. Eur. Arch. Psychiatry Clin. Neurosci. 2001, 251 (Suppl. 1), I8–I13.
  37. Ohi, K.; Kuwata, A.; Shimada, T.; Yasuyama, T.; Nitta, Y.; Uehara, T.; Kawasaki, Y. Response to benzodiazepines and the clinical course in malignant catatonia associated with schizophrenia: A case report. Medicine 2017, 96, e6566.
  38. Ungvari, G.S. Amineptine treatment of persistent catatonic symptoms in schizophrenia: A controlled study. Neuropsychopharmacol. Hung. 2010, 12.
  39. Ungvari, G.S.; Chiu, H.F.K.; Chow, L.Y.; Lau, B.S.T.; Tang, W.K. Lorazepam for chronic catatonia: A randomized, double-blind, placebo-controlled cross-over study. Psychopharmacol. 1999, 142, 393–398.
  40. Fricchione, G.L.; Cassem, N.H.; Hooberman, D.; Hobson, D. Intravenous lorazepam in neuroleptic-induced catatonia. J. Clin. Psychopharmacol. 1983, 3.
Subjects: Neurosciences
Contributors : , , ,
View Times: 73
Revisions: 2 times (View History)
Update Time: 07 Dec 2021
Table of Contents


    Are you sure to Delete?

    Video Upload Options

    Do you have a full video?
    If you have any further questions, please contact Encyclopedia Editorial Office.
    Edinoff, A.; Cornett, E.M.; Kaye, A.; Kaye, A.D. Catatonia: Diagnosis, Treatment and Clinical Challenges. Encyclopedia. Available online: (accessed on 01 July 2022).
    Edinoff A, Cornett EM, Kaye A, Kaye AD. Catatonia: Diagnosis, Treatment and Clinical Challenges. Encyclopedia. Available at: Accessed July 01, 2022.
    Edinoff, Amber, Elyse M. Cornett, Adam Kaye, Alan David Kaye. "Catatonia: Diagnosis, Treatment and Clinical Challenges," Encyclopedia, (accessed July 01, 2022).
    Edinoff, A., Cornett, E.M., Kaye, A., & Kaye, A.D. (2021, December 06). Catatonia: Diagnosis, Treatment and Clinical Challenges. In Encyclopedia.
    Edinoff, Amber, et al. ''Catatonia: Diagnosis, Treatment and Clinical Challenges.'' Encyclopedia. Web. 06 December, 2021.